One-year outcomes following imlifidase-enabled kidney transplantation in highly sensitized recipients: First Belgian experience.
Imlifidase, an IgG-cleaving enzyme, offers a novel desensitization strategy for highly sensitized kidney-transplant candidates with donor-specific antibodies (DSA). We report the first Belgian kidney recipient with a positive virtual crossmatch and treated with a single dose of imlifidase prior to transplantation. HLA...